Summit Therapeutics plc Summit Therapeutics File Us Annual Report On Form 20-F

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit", or the "Company") 
 
   SUMMIT THERAPEUTICS FILES US ANNUAL REPORT ON FORM 20-F 
 
   Oxford, UK, 31 March 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: 
SMMT), the drug discovery and development company advancing therapies 
for Duchenne muscular dystrophy and Clostridium difficile infection, 
provides notification that on 30 March 2017 the Company filed its US 
Annual Report on Form 20-F for the year ended 31 January 2017 with the 
US Securities and Exchange Commission ("SEC"). 
 
   The Form 20-F is available to download, either from the Investors 
section of the Company website at www.summitplc.com or from the SEC 
website at www.sec.gov. 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programs focused on the genetic disease, Duchenne 
muscular dystrophy, and the infectious disease, Clostridium difficile 
infection. Further information is available at www.summitplc.com and 
Summit can be followed on Twitter (@summitplc). 
 
   For more information, please contact: 
 
 
 
 
Summit Therapeutics 
 Glyn Edwards / Richard Pye (UK office)         Tel: +44 (0)1235 443 951 
 Erik Ostrowski / Michelle Avery (US office)    +1 617 225 4455 
Cairn Financial Advisers LLP 
 (Nominated Adviser)                            Tel: +44 (0)20 7213 0880 
 Liam Murray / Tony Rawlinson 
N+1 Singer 
 (Broker)                                       Tel: +44 (0)20 7496 3000 
 Aubrey Powell / Lauren Kettle 
MacDougall Biomedical Communications 
 (US media contact)                            Tel: +1 781 235 3060 
 Karen Sharma                                  ksharma@macbiocom.com 
Consilium Strategic Communications 
 (Financial public relations, UK)              Tel: +44 (0)20 3709 5700 
 Mary-Jane Elliott / Sue Stuart /              summit@consilium-comms.com 
 Jessica Hodgson / Lindsey Neville 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/

(END) Dow Jones Newswires

March 31, 2017 02:01 ET (06:01 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024